Adults with type 2 diabetes requiring insulin therapy can safely achieve good blood sugar control using regular human insulin (RHI) in a wearable, patch-like insulin delivery device called V-Go®.

Share:

FULL STORY

Adults with type 2 diabetes requiring insulin therapy can safely achieve good blood sugar control using regular human insulin (RHI) in a wearable, patch-like insulin delivery device called V-Go®, a new study finds. Results of the randomized controlled study -- which was accepted for presentation at ENDO 2020, the Endocrine Society's annual meeting, and will be published in a special supplemental section of the Journal of the Endocrine Society -- suggest "a more affordable option" for insulin therapy than newer insulin types, the researchers said.

"The modern insulins -- rapid acting insulin (RAI) analogs -- have dominated the mealtime insulin market for years, but skyrocketing prices have resulted in concerns of affordability and whether their differences from other available insulins are clinically relevant," said study lead investigator Pablo Mora, M.D., an endocrinologist at Dallas Diabetes Research Center at Medical City, Dallas, Texas.

When injected by an insulin pen or insulin syringe, RHI -- an older and less expensive insulin -- takes longer to reach the bloodstream and has a longer duration of action compared to modern RAIs, Mora said. These differences can influence blood glucose control, he noted.

V-Go is a 24-hour small, disposable mechanical device that, according to its manufacturer, Valeritas, Inc., is cleared for use with RAI in adults with diabetes, is easy to use and worn like a patch on the skin. It has the ability to deliver both a steady continuous subcutaneous infusion of insulin for 24 hours and mealtime insulin dosing on demand, Mora said.

The study was conducted at three study centers in the southern United States and evaluated the safety and effectiveness of delivering RHI with V-Go in 113 adults with type 2 diabetes who were currently using the device filled with RAI. The investigators randomly assigned 54 patients to continue using the V-Go with RAI, and they assigned another 59 patients to switch the insulin used to fill V-Go from RAI to RHI. Over the 14-week study, which Valeritas, Inc. supported with an educational grant, the researchers measured the between group difference in average change in hemoglobin A1c, a measure of long-term blood glucose control.

The research team reported that improvements in A1c were observed, with a decrease of 0.6% in the RHI group and a decrease of 0.38% in the RAI group. Mora also stated that the study met its primary endpoint of noninferiority, or similar blood glucose control. The researchers found no between-group differences in the total daily dose of insulin required or in episodes of low blood sugar, a measure of safety.

"By continuously infusing insulin for 24 hours with V-Go, differences in duration of insulin action are minimized between the two insulins. Our results support that RHI can be safely and effectively used when delivered by V-Go," Mora said, who reported receiving consulting and speaking fees from Valeritas, Inc.: "Use of RHI with V-Go expands the affordability of insulin therapy."

Story Source:

Materials provided by The Endocrine Society . Note: Content may be edited for style and length.

Cite This Page:

· MLA

· APA

· Chicago

The Endocrine Society. "Wearable device lets patients with type 2 diabetes safely use affordable insulin option." ScienceDaily. ScienceDaily, 31 March 2020. <www.sciencedaily.com/releases/2020/03/200331093256.htm>.

· Diabetes

· Wearable Technology

· Sports Science

· RELATED TERMS

· Insulin

· Diabetes mellitus type 2

· Diabetes mellitus type 1

· Diabetes

· South Beach diet

· Low-carb diets

· Insulin-like growth factor

· Glycogen

Mar. 21, 2021 — A new once-weekly basal insulin injection demonstrated similar efficacy and safety and a lower rate of low blood sugar episodes compared with a daily basal insulin, according to a phase 2 clinical ...

Diabetes: A Next-Generation Therapy Soon Available?

Oct. 16, 2019 — Insulin is normally produced by pancreatic beta cells. In many people with diabetes, pancreatic cells are not functional, causing a chronic and potentially fatal insulin deficiency that can only be ...

Our Bodies May Cure Themselves of Diabetes in the Future

Jan. 4, 2019 — Diabetes is caused by damaged or non-existing insulin cells inability to produce insulin, a hormone that is necessary in regulating blood sugar levels. Many diabetes patients take insulin supplements ...

Modified Insulin and Red Blood Cells Used to Regulate Blood Sugar

May 8, 2017 — Researchers have developed a new technique that uses modified insulin and red blood cells to create a glucose-responsive 'smart' insulin delivery system. In an animal model study, the new technique ...

FROM AROUND THE WEB

ScienceDaily shares links with sites in the TrendMD network and earns revenue from third-party advertisers, where indicated.

1. The Diabetes Epidemic: Spotlight on the U.S.

Author: Dawn DeWitt, IEEE PULSE, 2014

2. Self-care, A1C and stigmatization as predictors of a negative perception of insulin among adults with type 2 diabetes: a hospital-based study in Turkey

Hamdiye Arda Sürücü et al., Journal of Health Research, 2020

3. A randomised controlled trial to compare minimally invasive glucose monitoring devices with conventional monitoring in the management of insulin-treated diabetes mellitus (MITRE)

Clinical Governance: An International Journal, 2009

4. Effects of sour cherry juice on blood glucose and some cardiovascular risk factors improvements in diabetic women

Asal Ataie‐Jafari et al., Nutrition & Food Science, 2008

1. Researchers successfully test coin-sized smart insulin patch, potential diabetes treatment

by University of North Carolina Health Care, TechXplore.com

2. Effects of Processed Rye Bran and Raw Rye Bran on Glucose Metabolism in Alloxan Diabetic Rats

Charlotte Nygren et al., The Journal of Nutrition, 1982

3. Could genetic testing help your metastatic urothelial carcinoma patients? Visit FGFROncology to learn more.

Janssen, 2021

4. Revealing the molecular details in metastatic urothelial carcinoma could help you see your patients more clearly. Click to learn more.

Janssen, 2021

Print Email Share

Most Popular

this week

HEALTH & MEDICINE

New Discovery Shows Human Cells Can Write RNA Sequences Into DNA

Waking Just One Hour Earlier Cuts Depression Risk by Double Digits, Study Finds

An Omega-3 That's Poison for Tumors

MIND & BRAIN

Study Finds Brain Areas Involved in Seeking Information About Bad Possibilities

Bacteria Are Connected to How Babies Experience Fear

Rudeness Leads to Anchoring, Including in Medical Diagnoses

LIVING & WELL

Boy or Girl? It's in the Father's Genes

New Health Benefits of Red Seaweeds Unveiled

Science-Based Hiccups Intervention

Strange & Offbeat

HEALTH & MEDICINE

'Mosquito Smoothie' Innovation Boosts Future Malaria Vaccine Potential

Hippos and Anthrax

New Discovery Shows Human Cells Can Write RNA Sequences Into DNA

MIND & BRAIN

Researchers Translate a Bird's Brain Activity Into Song

Humans Are Ready to Take Advantage of Benevolent AI

Flickering Screens May Help Children With Reading and Writing Difficulties, Study Suggests

LIVING & WELL

Brain Connections Mean Some People Lack Visual Imagery

Bacteria Are Connected to How Babies Experience Fear

Microbial Gene Discovery Could Mean Greater Gut Health

· SD

· Health

· Tech

· Enviro

· Society

· Quirky

Top of Form

Bottom of Form

Free Subscriptions

Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

· Email Newsletters

· RSS Feeds

Follow Us

Keep up to date with the latest news from ScienceDaily via social networks:

· Facebook

· Twitter

· LinkedIn

Have Feedback?

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?

· Leave Feedback

· Contact Us

Content on this website is for information only. It is not intended to provide medical or other professional advice.

Views expressed here do not necessarily reflect those of ScienceDaily, its staff, its contributors, or its partners.

Financial support for ScienceDaily comes from advertisements and referral programs, where indicated.

— CCPA: Do Not Sell My Information — — GDPR: Privacy Settings —